TriSalus Life Sciences Inc. (TLSI) - Net Assets
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has net assets worth $6.55 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.45 Million) and total liabilities ($55.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See TLSI equity to assets ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.55 Million |
| % of Total Assets | 10.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
TriSalus Life Sciences Inc. - Net Assets Trend (2021–2025)
This chart illustrates how TriSalus Life Sciences Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see TriSalus Life Sciences Inc. stock valuation.
Annual Net Assets for TriSalus Life Sciences Inc. (2021–2025)
The table below shows the annual net assets of TriSalus Life Sciences Inc. from 2021 to 2025. Also explore TLSI net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-33.86 Million | -30.77% |
| 2024-12-31 | $-25.89 Million | +4.33% |
| 2023-12-31 | $-27.07 Million | -119.61% |
| 2022-12-31 | $-12.32 Million | -139.88% |
| 2021-12-31 | $30.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TriSalus Life Sciences Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19424100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | % |
| Other Components | $296.72 Million | % |
| Total Equity | $-33.86 Million | 100.00% |
TriSalus Life Sciences Inc. Competitors by Market Cap
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
$307.88 Million |
|
Interarch Building Products Limited
NSE:INTERARCH
|
$307.92 Million |
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
$307.97 Million |
|
Asia Aviation Public Company Limited
F:55AA
|
$307.97 Million |
|
Best Pacific International Holdings Limited
F:NWQ
|
$307.78 Million |
|
Oneconnect Financial Technology Co
NYSE:OCFT
|
$307.70 Million |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
$307.69 Million |
|
AVCON Information Tech
SHE:300074
|
$307.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TriSalus Life Sciences Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -25,894,000 to -33,861,000, a change of -7,967,000.
- Net loss of 39,227,000 reduced equity.
- Share repurchases of 404,000 reduced equity.
- New share issuances of 22,000,000 increased equity.
- Other factors increased equity by 9,664,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.23 Million | -115.85% |
| Share Repurchases | $404.00K | -1.19% |
| Share Issuances | $22.00 Million | +64.97% |
| Other Changes | $9.66 Million | +28.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares TriSalus Life Sciences Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.99 | $5.00 | x |
| 2022-12-31 | $-0.42 | $5.00 | x |
| 2023-12-31 | $-1.02 | $5.00 | x |
| 2024-12-31 | $-0.98 | $5.00 | x |
| 2025-12-31 | $-0.89 | $5.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TriSalus Life Sciences Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -86.88%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-18.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -93.34% | -343.35% | 0.22x | 1.22x | $-31.94 Million |
| 2022 | 0.00% | -380.60% | 0.56x | 0.00x | $-45.95 Million |
| 2023 | 0.00% | -320.69% | 0.75x | 0.00x | $-56.66 Million |
| 2024 | 0.00% | -112.92% | 1.23x | 0.00x | $-30.64 Million |
| 2025 | 0.00% | -86.88% | 1.28x | 0.00x | $-35.84 Million |
Industry Comparison
This section compares TriSalus Life Sciences Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,807,186,652
- Average return on equity (ROE) among peers: -42.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TriSalus Life Sciences Inc. (TLSI) | $6.55 Million | -93.34% | 8.53x | $307.87 Million |
| Abbott Laboratories (ABT) | $36.02 Billion | 19.63% | 1.09x | $179.96 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $5.06 Million |
| Aethlon Medical Inc (AEMD) | $15.06 Million | -79.86% | 0.16x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-879.00K | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $771.92 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.28 Million | -44.54% | 0.25x | $4.41 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $1.15 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $3.86 Million |
| Artivion Inc (AORT) | $7.30 Million | 9.59% | 0.70x | $1.14 Billion |
| Apyx Medical Inc (APYX) | $6.39 Million | 7.83% | 0.24x | $122.16 Million |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more